Editorial: Next generation B cell targeting therapies in autoimmune diseases

Rui Li; Jiahui Zhu; Shenyue Wang; Bo Zhang; Linlu Tian; Ying Fu

doi:10.3389/fimmu.2023.1322546

Editorial: Next generation B cell targeting therapies in autoimmune diseases

Front Immunol. 2023 Nov 9:14:1322546. doi: 10.3389/fimmu.2023.1322546. eCollection 2023.

Authors

Rui Li^{1

2

3}, Jiahui Zhu², Shenyue Wang², Bo Zhang⁴, Linlu Tian⁵, Ying Fu^{2

4}

Affiliations

¹ Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, China.
² Department of Neurology and Institute of Neurology of First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
³ Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
⁴ Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, Fujian, China.
⁵ Department of Immunology, Harbin Medical University, Harbin, Heilongjiang, China.

No abstract available

Keywords: B cell depleting therapies; B cell targeted therapy; Bruton tyrosine kinase (BTK); CAR (chimeric antigen receptor) T cells; NMO (neuromyelitis optica); SLE - systemic lupus erythematosus; multiple sclerosis; rituximab.

Publication types

Editorial

MeSH terms

Autoimmune Diseases* / drug therapy
Humans
Neuromyelitis Optica*
Spinal Cord

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.